GSK plc reports insider sales: 37,000 and 120,000 shares

GSK plc reported dealings by two senior executives.

Rhea-AI Filing Summary

GSK plc reported dealings by two senior executives. Regis Simard sold 37,000 Ordinary Shares at £16.8395 per share, and Deborah Waterhouse sold 120,000 Ordinary Shares at £16.8865 per share. Both transactions were single trades executed on the London Stock Exchange on 2025-10-29.

Insights

Securities disclosure analyst

Routine PDMR share sale disclosures; neutral impact.

GSK disclosed two reportable transactions by persons discharging managerial responsibilities. Regis Simard sold 37,000 Ordinary Shares at £16.8395, and Deborah Waterhouse sold 120,000 at £16.8865. Each was a single transaction on the London Stock Exchange on 2025-10-29.

These notifications fulfill market transparency rules and do not state any corporate action or funding event. The filing lists instrument identifiers and venues, consistent with standard practice.

Subsequent filings may provide additional PDMR dealings, if any, but this notice stands alone without broader strategic or financial implications.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK plc (GLAXF) disclose in this 6-K?

GSK reported two PDMR share sales on 2025-10-29, each a single transaction on the London Stock Exchange.

Who sold GSK (GLAXF) shares and how many?

Regis Simard sold 37,000 Ordinary Shares; Deborah Waterhouse sold 120,000 Ordinary Shares.

At what prices were the GSK (GLAXF) shares sold?

Regis Simard at £16.8395 per share; Deborah Waterhouse at £16.8865 per share.

When and where did the GSK (GLAXF) transactions occur?

Both trades occurred on 2025-10-29 on the London Stock Exchange (XLON).

What class of GSK (GLAXF) securities was involved?

Ordinary shares of 31¼ pence each, ISIN GB00BN7SWP63.

Are these aggregate transactions or multiple trades?

Each disclosure notes a single transaction with no aggregation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 12:20 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.8395	37,000
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-10-29
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.8865	120,000
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-10-29
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: 30 October, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc